The Future is Trippy? The FDA Starts Its First-Ever Study on Magic Mushrooms and Psychedelics

Voluntary Delisting: Summary & Explanation

Botanical Psilocybin & Alcohol Use Disorder: A Promising Treatment

Filament Health Announces FDA Authorization Of Phase 2 Clinical Trial Studying PEX010, The Company's Botanical Psilocybin Drug Candidate, In Opioid Use Disorder